1. Home
  2. BCDA vs HAO Comparison

BCDA vs HAO Comparison

Compare BCDA & HAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • HAO
  • Stock Information
  • Founded
  • BCDA N/A
  • HAO 2018
  • Country
  • BCDA United States
  • HAO China
  • Employees
  • BCDA N/A
  • HAO N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • HAO
  • Sector
  • BCDA Health Care
  • HAO
  • Exchange
  • BCDA Nasdaq
  • HAO NYSE
  • Market Cap
  • BCDA 11.0M
  • HAO 3.3M
  • IPO Year
  • BCDA N/A
  • HAO 2024
  • Fundamental
  • Price
  • BCDA $2.12
  • HAO $1.41
  • Analyst Decision
  • BCDA Strong Buy
  • HAO
  • Analyst Count
  • BCDA 1
  • HAO 0
  • Target Price
  • BCDA $25.00
  • HAO N/A
  • AVG Volume (30 Days)
  • BCDA 204.0K
  • HAO 28.8K
  • Earning Date
  • BCDA 08-12-2025
  • HAO 07-11-2025
  • Dividend Yield
  • BCDA N/A
  • HAO N/A
  • EPS Growth
  • BCDA N/A
  • HAO N/A
  • EPS
  • BCDA N/A
  • HAO 0.19
  • Revenue
  • BCDA $3,000.00
  • HAO $48,970,924.00
  • Revenue This Year
  • BCDA N/A
  • HAO N/A
  • Revenue Next Year
  • BCDA N/A
  • HAO N/A
  • P/E Ratio
  • BCDA N/A
  • HAO $7.22
  • Revenue Growth
  • BCDA N/A
  • HAO 15.04
  • 52 Week Low
  • BCDA $1.63
  • HAO $0.84
  • 52 Week High
  • BCDA $4.66
  • HAO $173.25
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 44.60
  • HAO 55.34
  • Support Level
  • BCDA $1.98
  • HAO $1.24
  • Resistance Level
  • BCDA $2.45
  • HAO $1.36
  • Average True Range (ATR)
  • BCDA 0.16
  • HAO 0.10
  • MACD
  • BCDA -0.01
  • HAO 0.01
  • Stochastic Oscillator
  • BCDA 18.00
  • HAO 85.96

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About HAO HAOXI HEALTH TECHNOLOGY LTD

Haoxi Health Technology Ltd is an online marketing solution provider in China, with an advertiser client base mainly in the healthcare industry. Haoxi has been rooted in the field of local online effect marketing for many years, serving customers in various industries at home and abroad, and its main business is the medical industry. It generates its revenue by providing one-stop online marketing solutions, in particular online short video marketing solutions, to advertisers through its media partners. The company provides customized marketing solutions by planning, producing, placing, and optimizing online ads, especially online short video ads, to help its advertisers acquire, convert, and retain ultimate consumers on various online media platforms.

Share on Social Networks: